The purpose of the REPAIR Impact Fund is to increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance.

Since 2018, the Novo Holdings REPAIR Impact Fund has invested in 12 companies. Moving forward, the Fund will focus on supporting its existing portfolio and is not currently conducting new calls.

Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovery and early-stage development of therapies targeting resistant microorganisms, hence the acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.

Since inception, The Fund has received and reviewed more than 300 proposals and invested in 12 companies. 

The primary goal for the REPAIR Impact Fund is to advance innovative anti-infective programs through phase 1 clinical proof of concept studies. Two programs have achieved this goal and the overall portfolio has seen good progress.

In 2023, REPAIR Impact Fund invested in Paratek, one of the largest independent antibiotics companies in the world. Paratek’s specialty pharmaceutical platform enables both the development and commercialisation of new drugs to bring new innovative therapies to patients.

With the remaining capital in the Fund, we hope to advance more projects from our portfolio through clinical transition and beyond.

Investing into new anti-microbial and anti-infective projects is difficult, so to ensure that our existing portfolio companies are able to advance their activities, we will focus our capital reserves on supporting them in a time where finding new investment partners is a challenge. Therefore, we will not open new calls for proposals.

Novo Holdings and the Novo Nordisk Foundation remain committed to combatting antimicrobial resistance, a critical global challenge and area of strategic focus. Our USD 50 million commitment to the AMR Action Fund remains, as does our USD 25 million to CARB-X. Additionally, we have established The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) and in cooperation with The Gates Foundation and Wellcome we have launched the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI).

Going forward, AMR will continue to be a central focus area for both the Novo Nordisk Foundation and Novo Holdings, and we will work on both supporting the pipeline for new antibiotics as well as increasing public awareness on the AMR-challenge and its possible solutions..

We are confident that the direction we have set for the REPAIR Impact Fund will serve our portfolio companies better, and ultimately be for the benefit of patients, when new innovative products hopefully reach the broader market.

Read how it works

See our answers to the most frequently asked questions about the Repair Impact Fund. Read more